Ticagrelor, marketed as Brilinta and Brilique, is an antiplatelet medication used to prevent thrombotic events like heart attack and stroke in individuals with acute coronary syndrome [1][2]. It functions by reversibly inhibiting the P2Y12 receptor on platelets, thereby reducing platelet activation and aggregation [3].
What is the global market size and forecast for Ticagrelor?
The global ticagrelor market was valued at approximately $4.1 billion in 2022 and is projected to grow to about $5.1 billion by 2030, reflecting a compound annual growth rate (CAGR) of 2.7% [4]. This growth is attributed to the increasing prevalence of cardiovascular diseases worldwide and the drug's established efficacy [4].
When does Ticagrelor's patent exclusivity expire?
Patent exclusivity for ticagrelor varies by region and specific patent. For instance, in the United States, key patents for ticagrelor have expired or are nearing expiry. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for ticagrelor in various markets [5].
What are the main indications and uses for Ticagrelor?
Ticagrelor is primarily prescribed for patients with acute coronary syndrome (ACS), including those who have had a heart attack or unstable angina, to reduce the rate of cardiovascular death, myocardial infarction, and stroke [1][2]. It is often used in combination with aspirin [1].
How does Ticagrelor work in the body?
Ticagrelor is a direct-acting, reversible antagonist of the P2Y12 adenosine diphosphate (ADP) receptor on platelets [3]. By blocking this receptor, it prevents ADP from binding, which in turn inhibits platelet activation and aggregation for up to 24 hours after administration. This mechanism is distinct from thienopyridines like clopidogrel, which require metabolic activation and have irreversible binding [3].
What are the key drivers of the Ticagrelor market growth?
The expanding patient pool due to the rising incidence of cardiovascular diseases, coupled with the demonstrated clinical benefits and physician preference for ticagrelor in ACS management, are significant market drivers [4]. Additionally, ongoing research exploring new indications and formulations can further contribute to market expansion [4].
What are the major challenges and risks for Ticagrelor?
The market faces challenges from the expiration of primary patents, leading to increased competition from generic versions [5]. Side effects such as bleeding events, dyspnea, and bradycardia are also patient concerns and clinical considerations [1][6]. Intense competition from other antiplatelet agents, both branded and generic, also poses a risk [5].
Who are the major competitors and alternatives to Ticagrelor?
Key competitors and alternatives to ticagrelor include other P2Y12 inhibitors such as clopidogrel (Plavix) and prasugrel (Effient) [7]. These drugs also target platelet aggregation but differ in their mechanism of action, onset of action, and bleeding profiles [3][7]. Generic versions of ticagrelor are also becoming increasingly available, intensifying competition [5].
What is the impact of generic competition on Ticagrelor pricing and market share?
The entry of generic ticagrelor products typically leads to a significant decrease in drug prices [5]. This price erosion can substantially impact the market share and revenue generated by the originator brand, as healthcare providers and payers shift towards more cost-effective generic options [5].
What are the latest clinical trial results or ongoing studies for Ticagrelor?
Ongoing research continues to evaluate ticagrelor in various clinical settings. Studies often focus on long-term efficacy, safety profiles in specific patient populations, and comparisons with other antiplatelet agents or treatment strategies [2][4]. DrugPatentWatch.com may track patent-protected research and development activities [5].
What are patient concerns or side effects associated with Ticagrelor?
Commonly reported side effects of ticagrelor include bleeding, dyspnea (shortness of breath), and bradycardia (slow heart rate) [1][6]. Patients and healthcare providers closely monitor for these adverse events to ensure safe and effective treatment.
How is Ticagrelor regulated, and what is its approval status?
Ticagrelor is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications related to cardiovascular disease prevention [1][2]. Regulatory approval signifies that the drug has met stringent standards for safety and efficacy [1][2].
Sources:
[1] https://www.nhs.uk/medicines/ticagrelor/
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/brilique
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047737/
[4] https://www.globenewswire.com/news-release/2023/08/10/2722984/0/en/Ticagrelor-Market-to-Reach-USD-5-1-Billion-by-2030-Growing-at-2-7-CAGR-Exclusive-Report-by-Coherent-Market-Insights.html
[5] https://drugpatentwatch.com/
[6] https://www.mayoclinic.org/drugs-supplements/ticagrelor-oral-route/side-effects/drh-20072012
[7] https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.116.023396